最新消息

汉康生技将于ASCO消化道肿瘤大会2026 发布 HCB101 联合标准治疗在第二线胃癌中的早期临床结果 剂量 […]

汉康生技 2025 年度里程碑总回顾 汉康为癌症及自身免疫疾病患者，打造具临床突破力的创新抗癌生物药。 汉康生 […]

HanchorBio Announces Oral Presentation of HCB101 at the […]

August 5th, 2022 – HanchorBio Inc. (“HanchorBio”), a biotechnology company pioneering the development of next-generation immunotherapies, today announced the successful completion of approximately US$20 million Series-A financing. The proceeds will enable HanchorBio to further expand and accelerate its growing pipeline of the proprietary Fc-based designer biologics (FBDB™) and to support the anticipated investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology studies, IND submissions, and the first part of phase 1 clinical trials.